On 10 August 2026 the Medicines and Healthcare products Regulatory Agency (MHRA) authorised orforglipron, to be marketed in the UK as Foundayo, for two licensed indications: weight loss and weight maintenance in specified adults, and improvement of glycaemic control in insufficiently controlled type 2 diabetes. The Agency stated that the decision makes the United Kingdom the first country in Europe to authorise this oral GLP-1 receptor agonist tablet.[1]

Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist. That structural distinction matters for a peptide reference. Unlike injectable semaglutide or tirzepatide, and unlike the oral semaglutide tablet authorised by the MHRA on 11 June 2026, orforglipron is not a peptide and does not rely on a sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC) absorption enhancer. The marketing authorisation therefore sits adjacent to the peptide literature rather than inside it. This article records the UK legal fact, the trial evidence the licence rests on, and what the decision does not change for unlicensed research compounds.

This is a news record of a licensing decision. It is not consumption, dosing, or self-administration advice. Peptide Data does not claim that orforglipron, or any other GLP-1 receptor agonist, treats, cures, or prevents any condition.

1. What the MHRA authorised

The marketing authorisation was granted to Eli Lilly on 10 August 2026.[1] Alongside a reduced-calorie diet and increased physical activity, orforglipron is authorised for weight loss and weight maintenance in adults with a body-mass index (BMI) of 30 kg/m² or above, or a BMI between 27 and 30 kg/m² with at least one weight-related comorbidity. It is separately authorised to improve glycaemic control in people whose type 2 diabetes is insufficiently controlled.[1][2]

Julian Beach, MHRA Executive Director of Healthcare Quality and Access, said the Agency had completed a rigorous assessment of safety, quality and effectiveness, and that “as with all GLP-1 receptor agonists, this is a prescription-only medication.”[1]

The authorised tablet is taken once daily and, unlike oral semaglutide, may be taken at any time of day with no food or water restrictions.[1][2] The marketing authorisation specifies a titration sequence beginning at 0.8 mg and escalating through 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg, with a minimum of one month at each dose level.[1] Those strengths are the licensed UK posology. They are not interchangeable with the 6 mg, 12 mg and 36 mg maintenance doses evaluated in the published ATTAIN-1 protocol (section 3). This article reports both as stated in their respective primary sources and does not map one onto the other.

The most common adverse reactions listed by the MHRA are nausea, constipation, diarrhoea, vomiting, dyspepsia and abdominal pain.[1]

2. Legal status in the United Kingdom

Orforglipron is a prescription-only medicine (POM) under the Human Medicines Regulations 2012. Supply otherwise than in accordance with a valid prescription issued by an appropriate practitioner is an offence. The MHRA has restated that all GLP-1 medicines can be obtained only from a registered pharmacy against a prescription, that buying them from unregulated sellers carries serious health risks, and that it is unlawful to advertise a POM to the public.[1]

A marketing authorisation is not an NHS commissioning decision. The MHRA states that the tablet is not currently available via the NHS and that decisions on NHS use will follow established processes, including evaluation by the National Institute for Health and Care Excellence (NICE).[1] The Pharmaceutical Journal reports that NICE guidance on orforglipron for managing overweight and obesity is in development, with publication expected on 18 November 2026.[2] Until that appraisal concludes, and until any subsequent NHS commissioning takes effect, the licensed product is not a routinely funded NHS medicine.

The authorisation does not reclassify unlicensed research peptides, does not create a general retail market in GLP-1 receptor agonists, and does not authorise compounding or research-chemical supply of orforglipron or of peptide GLP-1 analogues.

3. Evidence underlying the licence: ATTAIN-1

The weight-management indication is supported by ATTAIN-1, a 72-week, Phase 3, randomised, double-blind, placebo-controlled trial in 3,127 adults with obesity, or overweight plus one weight-related comorbidity, and without diabetes. Participants were enrolled in nine countries. Mean baseline weight was 103.2 kg and mean BMI 37.0 kg/m². Randomisation was to once-daily orforglipron 6 mg, 12 mg or 36 mg, or placebo. Results were presented at the 61st European Association for the Study of Diabetes Annual Meeting and published in the New England Journal of Medicine on 16 September 2025.[3][4][5]

Two estimands were reported. The efficacy estimand estimates the treatment effect if all participants had adhered to the assigned regimen. The treatment-regimen estimand estimates the effect regardless of discontinuation and is the more conservative figure for regulatory reading.

Mean percent change in body weight at 72 weeks, treatment-regimen estimand:[3][4][5]

  • orforglipron 6 mg: −7.5%
  • orforglipron 12 mg: −8.4%
  • orforglipron 36 mg: −11.2%
  • placebo: −2.1%

The corresponding efficacy-estimand figures were −7.8%, −9.3% and −12.4% versus −0.9% with placebo.[3][4][5] All three doses met the primary endpoint of superior body-weight reduction versus placebo. On the efficacy estimand, 59.6% of participants on 36 mg lost at least 10% of body weight and 39.6% lost at least 15%.[3][4]

ATTAIN-1 excluded people with type 1 or type 2 diabetes. The type 2 diabetes indication rests on the separate ACHIEVE programme. ACHIEVE-3, a head-to-head comparison with oral semaglutide in insufficiently controlled type 2 diabetes, has already been reported on this site and is not re-analysed here.[2]

These figures describe randomised trial populations under protocol conditions. They are not forecasts of individual outcome and they are not a basis for unlicensed use.

4. How this sits next to oral semaglutide

The MHRA authorised a 25 mg once-daily semaglutide tablet (Wegovy) for weight management on 11 June 2026, on the basis of OASIS 4.[6] That product is a peptide GLP-1 receptor agonist formulated for oral absorption and requires an overnight fast and a post-dose restriction on food and drink. Orforglipron is a non-peptide agonist with no such restrictions.[1][2]

The two licences should not be read as a head-to-head comparison. OASIS 4 and ATTAIN-1 enrolled different populations, ran for different durations (64 versus 72 weeks), and used different estimands and dose constructs. Cross-trial arithmetic is not evidence of relative efficacy. What can be stated is narrower: as of August 2026 the UK has two authorised oral GLP-1 receptor agonist tablets, only one of which is a peptide, and neither is commissioned on the NHS pending NICE.

An earlier Peptide Data article recorded the US Food and Drug Administration’s April 2026 approval of orforglipron (Foundayo). That is a different jurisdiction. The 10 August decision is the first European marketing authorisation.

5. Safety signals already on the UK record

The MHRA continues to apply class-level GLP-1 warnings to authorised products in this group, including acute pancreatitis (including necrotising and fatal cases), pulmonary aspiration risk before anaesthesia or deep sedation, and — for semaglutide specifically — a very rare risk of non-arteritic anterior ischaemic optic neuropathy (NAION). Those signals are documented in existing Peptide Data safety articles and are not repeated at length here. Whether every class warning is reproduced verbatim on the Foundayo summary of product characteristics will be clear once that document is published on the MHRA Products website; the Agency said the SmPC and patient information leaflet would appear within seven days of authorisation.[1]

Gastrointestinal adverse events were the dominant tolerability finding in ATTAIN-1, consistent with the GLP-1 receptor agonist class.[3][5] The MHRA will keep the safety of orforglipron under review through the Yellow Card scheme.[1]

6. What this does not change for research peptides

A marketing authorisation for a finished medicinal product is not a licence to possess, compound, or supply unlicensed peptides for human use. Semaglutide, tirzepatide and now orforglipron remain POMs when supplied as licensed medicines. Research-chemical listings that invoke those names, or that offer “research-use” oral GLP-1 tablets, are not covered by this authorisation.

Under the Medicines Act 1968 and the Human Medicines Regulations 2012, a substance presented for the treatment or prevention of disease, or administered with a view to modifying a physiological function, is a medicinal product. Labelling a vial or tablet “for research only” does not displace that analysis where the circumstances of supply point to human administration. Peptide Data’s compound profiles continue to treat unlicensed peptides as research compounds, not as alternatives to licensed POMs.

7. What to watch next

Three items will determine how much this licence matters in UK practice.

First, the Foundayo SmPC. Until it is on the MHRA Products register, the licensed posology, contraindications and class-warning language should be read from the 10 August notice rather than from US prescribing information or from the ATTAIN-1 protocol.

Second, NICE. An obesity-management appraisal is in train, with the Pharmaceutical Journal reporting an expected publication date of 18 November 2026.[2] A positive recommendation would still leave commissioning, service capacity and eligibility criteria to be settled, as they were after TA875 (semaglutide) and TA1026 (tirzepatide).

Third, supply-chain integrity. The MHRA has already issued a drug-safety update on falsified Mounjaro (tirzepatide) 15 mg KwikPens in 2026. An oral tablet is a different presentation with a different counterfeit profile. Any Yellow Card cluster or falsified-product alert will be material.

Until those three items move, the accurate statement is limited: orforglipron is now a UK-licensed POM; it is not an NHS medicine; it is not a peptide; and it does not alter the research-use-only status of unlicensed compounds on this site.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.